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Introduction: Insulin-like growth factors (IGFs), IGF binding proteins (IGFBPs) and angiopoietin-like proteins
(ANGPTLs) can enhance the ex vivo expansion of hematopoietic stem cells (HSCs) when used with a standard
cytokine cocktail of stem cell factor (SCF), thrombopoietin (TPO) and FLT3 ligand (FL). In order to determine the
optimal dose and combination of IGFs, IGFBPs and ANGPTLs, serial dilution and full permutation of IGFBP1, IGFBP2,
IGF2 and ANGPTL3 were applied on a cryopreserved umbilical cord blood mononuclear cell (UCB-MNC) ex vivo
expansion system.
Methods: In this system, 4 × 105 cells/ml of UCB-MNCs were inoculated in serum-free Stemspan® medium (Stemcell
technologies, vancouver, BC, Canada) supplied with standard basal cytokine combination of 100 ng/ml SCF, 50 ng/
ml FL and 100 ng/ml TPO and supported by a bone marrow mesenchymal stromal cell layer.
Results: Paradoxically, experiment results showed that the highest expansion of CD34+CD38−CD90+ primitive
progenitor was stimulated by cytokine combination of SCF + TPO + FL + IGFBP1 + IGFBP2 + ANGPTL3 at a low dose
of 15 ng/ml IGFBP1 and 20 ng/ml IGFBP2 and ANGPTL3. This ex vivo expansion was further validated in 8-week-old
to 10-week-old nonobese diabetic/severe combined immunodeficiency interleukin 2 gamma chain null (NOD/
SCID-IL2Rγ−/−) mice. Limiting dilution assay showed excellent correlation between the HSC ex vivo surface marker of
CD34+CD38−CD90+ and the in vivo competitive repopulating unit (CRU) functional assay.
Conclusion: IGFBP1, IGFBP2, IGF2 and ANGPTL3 can stimulate the expansion of CD34+CD38−CD90+ primitive
progenitor at low dose. The optimal combination comprises IGFBP1, IGFBP2 and ANGPTL3 together with the
standard cytokine cocktail of SCF, FL and TPO. The CD34+CD38−CD90+ phenotype can serve as a surrogate
ex vivo surface marker for HSCs due to consistency with the in vivo CRU functional assay.* Correspondence: william.hwang.y.k@sgh.com.sg
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Table 1 Cord blood unit phonotype information
Unit used in experiment CD34+ cells (%) CD34+CD38−CD90+
cells (%)
Figure 1 2.6 0.10
Figure 2 1.3 0.06






Figures 4 and 5 1.6 0.08
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Ex vivo expansion of umbilical cord blood (UCB) hema-
topoietic stem cells (HSCs) may overcome the obstacle of
low cell dose for UCB transplantation in adults. Insulin-like
growth factors (IGFs), insulin-like growth factor binding
proteins (IGFBPs) and angiopoietin-like proteins (ANGPTLs)
have been described previously to help enhance ex vivo
expansion of HSCs when used with a standard cytokine
cocktail of stem cell factor (SCF), thrombopoietin (TPO)
and FLT3 ligand (FL) [1-10]. ANGPTLs and IGFBPs have
also been demonstrated to enhance HSC in vivo migration
and activity, supporting survival and replating capacity
[11-14]. However, the optimal dose and combination of
these novel cytokines have yet to be determined. Current
doses of IGFBPs and ANGPTLs are in the range of 100 to
500 ng/ml. In terms of clinical application, these concen-
trations may not be optimal and would be costly. Hence,
investigations into the optimal cytokine dose and combin-
ation of IGFs, IGFBPs and ANGPTLs are important.
In this study, serial dilution and full permutation were used
to determine the optimal cytokine dose and combination for
stimulation of ex vivo expansion of UCB-HSCs. This estab-
lished cytokine dose and combination were then further
validated in 8-week-old to 10-week-old nonobese diabetic/
severe combined immunodeficiency interleukin 2 receptor
gamma chain null (NOD/SCID-IL2Rγ−/−; NSG) mice.
Methods
Cell preparation
Cryopreserved UCB was obtained from Singapore Cord
Blood Bank. Bone marrow (BM) was obtained from
Singapore General Hospital with the donor’s informed
consent. The use of UCB and BM was reviewed and ap-
proved by the Institutional Review Boards of National
University of Singapore, Singapore General Hospital as
well as the Singapore Cord Blood Bank Research Advis-
ory Ethics Committee (for UCB). Cryopreserved UCB
was processed in Singapore Cord Blood Bank following
the standard volume reduction and red blood cell deple-
tion method. The characteristics of the UCBs employed
in this study are summarized in Table 1. BM-derived
mesenchymal stromal cell culture was obtained as de-
scribed in our previous publication [15,16].
Cell culture
Cryopreserved UCB mononuclear cells (4 × 105cells/ml)
were suspended in serum-free Stemspan® medium (Stemcell
technologies, vancouver, BC, Canada) supplied with a
standard cytokine combination of 100 ng/ml SCF, 50 ng/
ml FL and 100 ng/ml TPO (all three cytokines purchased
from Peprotech, Rocky Hill, NJ, USA) and with individu-
ally varied doses and combinations of IGFBP1, IGFBP2,
IGF2 and ANGPTL3 (these four cytokines purchased
from R&D Systems, Minnneapolis, MN, USA). The cellswere inoculated on a passage 3 to 5 BM-derived mesen-
chymal stromal cell layer and cultured in 37°C incubator
for 12 days. The expanded cells were harvested at the end
of 12 days and the adherent cord blood cells were detached
after 1 minute of incubation at room temperature with
0.25% trypsin–ethylenediamine tetraacetic acid.
Flow cytometric analysis
All data were acquired using the cytomics FC500 flow
cytometer (Beckman Coulter, Inc., Miami, FL, USA) and
10,000 events per sample were collected. Cell viability
(AnnV/7AAD), hematopoietic primitive progenitors (CD34/
CD38/CD90) of unexpanded and ex vivo expanded UCB
and human cell multi-lineage reconstitution (CD45, CD34,
CD71, CD15/66b, CD3 and CD19/20) in mice were ana-
lyzed using the same method mentioned in our previously
published paper [15,16].
Methylcellulose colony assays
Quantification of granulocyte–macrophage colony-forming
units was performed before and after expansion. The
method was similar to our previous publication [15,16].
NOD/SCID-IL2Rγ−/−mice transplantation
NSG mice were purchased from Jackson Laboratories
(Klaine, USA) by SingHealth Experimental Medicine
Centre and were maintained in the same facility. All animal
experiments were performed under the approval of the
SingHealth Institutional Animal Care and Use Committee.
The unexpanded and expanded UCB with four different
cytokine combinations, ‘SCF+TPO+FL’, ‘SCF+TPO+FL+
IGFBP2’, ‘SCF + TPO+ FL + IGFBP2 + IGF2 + ANGPTL3’
and ‘SCF +TPO+ F + IGFBP1 + IGF2 +ANGPTL3’ at doses
of 20 ng/ml IGFBP2 and ANGPTL3, 15 ng/ml IGFBP1
and 10 ng/ml IGF2, were injected intravenously via the tail
vein into sublethally irradiated (240 cGy) 8-week-old to
10-week-old NSG mice. Acidified water and cyclosporine
A were administered to NSG mice orally and by
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fungal infection and graft versus host disease.
Harvesting of mouse bone marrow
At the end of the fourth month of transplantation, the
mice were sacrificed using a carbon dioxide chamber.
The femur and tibia were harvested and placed into
cold RPMI medium (Invitrogen, Grand Island, NY,
USA) immediately. Joint ends were cut and BM was
flushed out with 10 ml of 2% fetal bovine serum–RPMI.
Subsequently, contaminated red blood cells were lysed
by ammonium chloride-based buffer before flow cyto-
metric analysis.
Statistical analysis
The results are expressed as mean ± standard deviation.
The significance between two groups was determined
using the two-sample independent t test. P < 0.05 was
defined as significant. In terms of multiple comparisons,
Bonferroni’s test was used to correct the P value for theFigure 1 IGFBP1, IGFBP2, IGF2 and ANGPTL3 stimulate the ex vivo ex
Post-thaw umbilical cord blood cells (4 × 105 cells/ml) were suspended in s
Canada) supplied with different doses of indicated cytokines in the range 0
cell factor, 50 ng/ml FLT3 ligand and 100 ng/ml thrombopoietin, inoculate
layer in a 24-well plate and cultured for 12 days. (A) Expansion of viable to
of granulocyte–macrophage colony-forming units (CFU-GM). (D) Expansion
deviation. For each novel cytokine, a t test was performed between the va
combination). **P < 0.01. ANGPTL, angiopoietin-like protein; IGF, insulin-liket test. The processing and statistical analysis of the data
was performed using OriginPro 7.5 software (OriginPro,
Inc., Northampton, MA, USA).
Results
Low dose of IGFBP1, IGFBP2, IGF2 and ANGPTL3 is enough
to boost the ex vivo expansion of CD34+CD38−CD90+
primitive progenitor cells
When cryopreserved UCB mononuclear cells were cul-
tured on a BM-derived mesenchymal stromal cell layer
with the standard cytokine cocktail (100 ng/ml SCF, 50
ng/ml FL and 100 ng/ml TPO) plus individually varied
doses of IGFBP1, IGFBP2, IGF2 and ANGPTL3, the high-
est expansion of CD34+CD38−CD90+ primitive progenitor
appeared at a low dose of 20 ng/ml for IGFBP1, IGFBP2,
IGF2 and ANGPTL3 (concentrations of 0, 20, 50, 100 and
200 ng/ml were studied) (Figure 1D). The expansion of
total nucleated cells, CD34+ cells and granulocyte–macro-
phage colony-forming units decreased with increasing
dose of cytokine (Figure 1A,B,C). Based on the abovepansion of CD34+CD38−CD90+ primitive progenitors at low dose.
erum-free Stemspan® media (Stemcell technologies, vancouver, BC,
to 200 ng/ml and standard cytokine combinations of 100 ng/ml stem
d on a passage 3 to 5 bone marrow-derived mesenchymal stromal cell
tal nucleated cells (TNCs). (B) Expansion of CD34+ cells. (C) Expansion
of CD34+CD38−CD90+ cells. Results expressed as mean ± standard
riant cytokine dosage group and baseline (standard cytokine
growth factor; IGFBP, insulin-like growth factor binding protein.
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to 0 to 50 ng/ml. The optimal cytokine dose was deter-
mined at 20 ng/ml IGFBP2 and ANGPTL3, 15 ng/ml
IGFBP1 and 10 ng/ml IGF2 when maximal expansion of
CD34+CD38−CD90+ primitive progenitor was reached,
which was significantly higher than standard cytokine
combination (P = 0.01) (Figure 2D). Similarly, these four
novel cytokines did not contribute to the expansion of total
nucleated cells, CD34+ cells and granulocyte–macrophage
colony-forming units (Figure 2A,B,C).
‘SCF + TPO + FL + IGFBP1 + IGFBP2 + ANGPTL3’ is the
optimal combination to enhance ex vivo expansion of
CD34+CD38−CD90+ primitive progenitor cells
To determine the optimal cytokine combination, complete
permutation was carried out after establishing the optimal
dose of each cytokine. The combination ‘SCF +TPO+ FL +
IGFBP1 + IGFBP2 +ANGPTL3’ had superior expansion of
CD34+CD38−CD90+ primitive progenitor (16.3 ± 3.9-fold
versus 7.5 ± 1.9-fold with standard cytokine cocktail)Figure 2 Optimal dose of IGFBP1, IGFBP2, IGF2 and ANGPTL3 was est
(4 × 105 cells/ml) were suspended in serum-free Stemspan® media (Stemce
of indicated cytokines in the range 0 to 50 ng/ml and standard cytokine co
100 ng/ml thrombopoietin, inoculated on a passage 3 to 5 bone marrow-d
for 12 days. (A) Expansion of viable total nucleated cells (TNCs). (B) Expansion o
units (CFU-GM). (D) Expansion of CD34+CD38−CD90+ cells. Results expressed
performed between the variant cytokine dosage group and baseline (standar
IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding proteincompared with all other combinations (Figure 3D). Simi-
larly, despite promoting expansion of CD34+CD38−CD90+
primitive cells, there was no further enhancement of ex-
pansion of total cells and general progenitors compared
with control (Figure 3A,B,C), suggesting that this cytokine
cocktail only enhanced the earlier progenitors. Hence,
representative cytokine cocktails of ‘SCF + TPO + FL’,
‘SCF + TPO+ FL + IGFBP2’, ‘SCF + TPO+ FL + IGFBP2 +
IGF2+ANGPTL3’ and ‘SCF+TPO+FL+ IGFBP1+ IGFBP2+
ANGPTL3’ were chosen for further validation in NSG mice.
Equivalent human cell engraftment and multi-lineage
reconstitution profile between unexpanded and
expanded umbilical cord blood
NSG repopulation assays were performed to determine
whether the ex vivo expanded cells were capable of
long-term hematopoiesis. Thus, 5 × 105 and 1 × 106
unexpanded cells and 1 × 106 and 2 × 106 expanded cells
with four cytokine combinations of ‘SCF + TPO + FL’,
‘SCF + TPO+ FL + IGFBP2’, ‘SCF + TPO+ FL + IGFBP2 +ablished from 10 to 20 ng/ml. Post-thaw umbilical cord blood cells
ll technologies, vancouver, BC, Canada) supplied with different doses
mbinations of 100 ng/ml stem cell factor, 50 ng/ml FLT3 ligand and
erived mesenchymal stromal cell layer in a 24-well plate and cultured
f CD34+ cells. (C) Expansion of granulocyte–macrophage colony-forming
as mean ± standard deviation. For each novel cytokine, the t test was
d cytokine combination). **P < 0.01. ANGPTL, angiopoietin-like protein;
.
Figure 3 ‘SCF + TPO + FL + IGFBP1 + IGFBP2 + ANGPTL3’ is the optimal cytokine combination to enhance ex vivo expansion of CD34
+CD38−CD90+ primitive progenitor cells. Post-thaw umbilical cord blood cells (4 × 105 cells/ml) were suspended in serum-free Stemspan®
media (Stemcell technologies, vancouver, BC, Canada) supplied with different cytokine combinations with optimal doses and standard cytokine
combinations of 100 ng/ml stem cell factor (S), 50 ng/ml FLT3 ligand (F) and 100 ng/ml thrombopoietin (T), inoculated on a passage 3 to 5 bone
marrow-derived mesenchymal stromal cell layer in a 24-well plate and cultured for 12 days. Here, the optimal dose of IGFBP1 (A), IGFBP2 (B), IGF2
(C) and ANGPTL3 (D) was 15 ng/ml, 20 ng/ml, 10 ng/ml and 20 ng/ml respectively. (A) Expansion of viable total nucleated cells (TNCs). (B) Expansion
of CD34+ cells. (C) Expansion of granulocyte–macrophage colony-forming units (CFU-GM). (D) Expansion of CD34+CD38−CD90+ cells. Results expressed
as mean ± standard error (cord blood unit number, n= 6). ANGPTL, angiopoietin-like protein; IGF, insulin-like growth factor; IGFBP, insulin-like growth
factor binding protein.
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ANGPTL3’ were transplanted to irradiated NSG mice.
The results did not demonstrate any significant difference
in the human cell long-term engraftment when the mice
received UCB expanded with cytokine combinations of
‘SCF +TPO+ FL’, ‘SCF +TPO+ FL + IGFBP2’, ‘SCF +TPO+
FL+ IGFBP2 + IGF2 +ANGPTL3’ and ‘SCF +TPO+FL +
IGFBP1 + IGFBP2 + ANGPTL3’ compared with unexpan-
ded UCB (P < 0.05; Figure 4A). This means that the stem
cell repopulation properties were not lost during the
ex vivo expansion. In addition, representative mice that re-
ceived 2 × 106 expanded cells cultured with the cytokine
combination ‘SCF+FL+TPO+IGFBP1+ IGFBP2+ANGPTL3’
displayed an equivalent multi-lineage differentiation cap-
acity of primitive human cells (CD34+, 0.26 ± 0.11%), mye-
loid cells (CD45+CD71+, 0.2 ± 0.08%; CD15/66b+, 0.16 ±
0.07%), B-lymphoid cells (CD19/20+, 0.87 ± 0.56%) and
T-lymphoid cells (CD3+, 0.01 ± 0.001%) to mice thatreceived 0.5 × 106 unexpanded cells of 0.36 ± 0.23%, 0.52 ±
0.32%, 0.47 ± 0.36%, 0.47 ± 0.27% and 2.15 ± 0.82% (P =
0.81, P = 0.58, P = 0.64, P = 0.50 and P = 0.15; Figure 4B).
For T-lymphoid cell differentiation, even though there was
no significant difference between expanded units and unex-
panded units from statistical analysis, from direct observa-
tion we could say that the unexpanded unit was better than
the expanded unit.
Phenotypic marker of CD34+CD38−CD90+ can be used as
a hematopoietic stem cell ex vivo detecting marker
After 4 months of transplantation, the limiting dilution
assay showed that the competitive repopulating unit
(CRU) was 1/1.53 × 106, 1/1.6 × 106, 1/1.4 × 106 and 1/
1.2 × 106 in the expanded cells cultured with cytokine
combinations of ‘SCF + TPO + FL’ , ‘SCF + TPO + FL +
IGFBP2’ , ‘SCF + TPO + FL + IGFBP2 + IGF2 + ANGPTL3’
and ‘SCF+TPO+FL+ IGFBP1+ IGFBP2+ANGPTL3’ com-
Figure 4 Human cell engraftment and multi-lineage reconstitution profile. (A) Amount of human chimerism in the bone marrow of NOD/
SCID-IL2Rγ−/−mice that received a transplant of 5 × 105 and 1 × 106 unexpanded human mononuclear cord blood cells and 1 × 106 and 2 × 106
expanded progeny cells. Each symbol represents the engraftment of a single mouse that underwent transplantation assayed at 4 months post
transplantation. (B) Summary of multi-lineage reconstitution from mice bone marrow transplanted 5 × 105 unexpanded cells in lane 1 and
transplanted 2 × 106 expanded cells with the cytokine combination ‘S + F + T + ABD’ in lane 10 of (A). S, stem cell factor; F, FLT3 ligand; T,
thrombopoietin. A, IGFBP1; B, IGFBP2; C, IGF2; D, ANGPTL3. ANGPTL, angiopoietin-like protein; IGF, insulin-like growth factor; IGFBP, insulin-like
growth factor binding protein.
Fan et al. Stem Cell Research & Therapy 2014, 5:71 Page 6 of 9
http://stemcellres.com/content/5/3/71pared with 1/6.1 × 105 in the unexpanded cells when
P < 0.05 (Figure 5A). There was thus 4.4-fold, 4.3-fold,
4.5-fold and 6.4-fold in vivo expansion of long-term
HSCs based on calculation according to the viable total
nucleated cell expansion (Figure 5B, lane 1). There was
6.4 ± 0.2-fold, 6.0 ± 0.1-fold, 6.8 ± 0.2-fold and 8.8 ± 0.5-fold ex vivo expansion of CD34+CD38−CD90+ cells ac-
cording to these four cytokine combinations (Figure 5B,
lane 4). Strangely, there is always a close ratio of 69.8 ±
2.9% between in vivo expansion of the CRU and ex vivo
expansion of CD34+CD38−CD90+ cells in different cyto-
kine combinations (Figure 5C). The excellent correlation
Figure 5 Cytokine combination of ‘SCF + TPO + FL + IGFBP1 + IGFBP2 + ANGPTL3’ stimulates highest ex vivo expansion of primitive
progenitors as assayed in NOD/SCID-IL2Rγ−/−mice. (A) Limiting dilution assay for the unexpanded and expanded cells. Negative engraftment
was defined by less than 0.5% of human CD45+ cell engraftment in mice bone marrow (P < 0.05). (B) Ex vivo expansion of umbilical cord blood
(UCB) cells. Post-thaw UCB cells (4 × 105 cells/ml) were suspended in serum-free Stemspan® media (Stemcell technologies, vancouver, BC, Canada)
supplied with cytokine combinations of ‘S + T + F’,’ S + T + F + B’,’ S + T + F + BCD’ and ‘S + T + F + ABD’ respectively, inoculated on a passage 3 to 5
bone marrow-derived mesenchymal stromal cell layer in a T175 flask and cultured for 12 days. Here, the concentration of stem cell factor (S), FLT3
ligand (F), thrombopoietin (T), IGFBP1 (A), IGFBP2 (B), IGF2 (C) and ANGPTL3 (D) was 100 ng/ml, 50 ng/ml, 100 ng/ml, 15 ng/ml, 20 ng/ml, 10 ng/ml
and 20 ng/ml respectively. (C) Correlation of in vivo competitive repopulating unit (CRU) functional assay and ex vivo CD34+CD38−CD90+ cell
surface marker. Results expressed as mean ± standard deviation. For multiple comparisons, Bonferroni’s test was used to correct the P value for
the t test. P < 0.05→ Pcorrected < 0.017 and P < 0.01→ Pcorrected < 0.003 when n = 3. *P < 0.05, **P < 0.01. ANGPTL, angiopoietin-like protein;
CFU-GM, granulocyte–macrophage colony-forming units; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; TNC,
total nucleated cell.
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CD38−CD90+ and the in vivo CRU functional assay indi-
cate that phenotypic combination of CD34+CD38−CD90+
can be used as an HSC ex vivo detecting biomarker.Discussion
In this study, IGFBP1, IGFBP2, IGF2 and ANGPTL3
have been demonstrated to stimulate ex vivo expansion
of CD34+CD38−CD90+ primitive progenitor at a low
dose of 15 ng/ml IGFBP1, 10 ng/ml IGF2 and 20 ng/ml
IGFBP2 and ANGPTL3. The optimal cytokine combin-
ation comprises IGFBP1, IGFBP2 and ANGPTL3 to-
gether with the standard cytokine cocktail of SCF, FL
and TPO. In view of the excellent correlation between
the HSC ex vivo surface marker of CD34+CD38−CD90+
and the in vivo CRU functional assay, the CD34+CD38−CD90+ phenotype can serve as an ex vivo surrogate sur-
face marker for HSCs.
We showed that IGFBP1, IGFBP2, IGF2 and ANGPTL3
could stimulate the ex vivo expansion of HSCs or primi-
tive progenitors rather than common progenitors and
total cells, in agreement with recent reports [4,6,7,9,10].
However, this stimulation had a negative correlation to
cytokine dose, where a high dose of cytokine induced
low expansion of primitive progenitors. In fact, the opti-
mal cytokine dose appeared at the lower range of 10 to
20 ng/ml. Compared with 100 to 500 ng/ml high-dose
cytokine usage, this 10 to 20 ng/ml low dose will help to
dramatically reduce the cost in clinical applications.
In addition, our data also showed that an expanded
unit with the established optimal cytokine cocktail of
‘SCF + TPO + FL + IGFBP1 + IGFBP2 + ANGPTL3’ had
the capacity of multi-lineage reconstitution except for
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showed that there was no significant difference on
T-lymphoid cell differentiation between expanded units
and unexpanded units, T-lymphoid reconstitution capacity
from the unexpanded unit was better than from the ex-
panded unit by direct observation. The explanation for
this phenomenon could be due to the cytokine cocktail
used in ex vivo expansion to drive cultured cells to expand
and differentiate into the myeloid lineage rather than the
T-lymphoid lineage (data not shown). This defect can be
overcome by double cord blood transplantation with one
expanded unit and one unexpanded unit as demonstrated
in our previous publication [15,16].
From the limiting dilution assay, we know that only
about 70% of expanded CD34+CD38−CD90+ primitive
progenitors will reconstitute in NSG mice. What then
happens to that 30% of expanded CD34+CD38−CD90+
primitive progenitors? We postulate two possibilities; the
first is that 30% of expanded CD34+CD38−CD90+ primi-
tive progenitors lose their in vivo reconstitution capacity
during ex vivo expansion even though they express the
biomarker phenotypically, while the second possibility
could be that 70% of expanded CD34+CD38−CD90+
primitive progenitors possess self-renewal, pluripotency
and long-term reconstitution capacity, whereas only 30%
of them have short-term hematopoietic reconstitution
capacity.
Conclusions
IGFBP1, IGFBP2, IGF2 and ANGPTL3 can stimulate
ex vivo expansion of CD34+CD38−CD90+ primitive pro-
genitor at low dose with the optimal cytokine combination
comprising IGFBP1, IGFBP2 and ANGPTL3 together
with the standard cytokine cocktail of SCF, FL and TPO.
The CD34+CD38−CD90+ phenotype can serve as a surro-
gate ex vivo surface marker for HSC detection due to
consistency with the in vivo CRU functional assay.
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